Oxidative Stress and Oval Cell Accumulation in Mice and Humans with Alcoholic and Nonalcoholic Fatty Liver Disease

Tania Roskams(KU Leuven), Anna Mae Diehl(Duke Medical Center), Xiawen Huang(Johns Hopkins University), Ruth Achten(Jessa Hospital), Aymen Koteish(Johns Hopkins University), Shi Qi Yang(Johns Hopkins University), Chris Verslype(Universitair Ziekenhuis Leuven), R Devos(KU Leuven), Anne Durnez(Cliniques Universitaires Saint-Luc)

American Journal Of Pathology

October 1, 2003

10.1016/s0002-9440(10)63489-x

Cited by 448

Related Papers

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

|New England Journal of Medicine|2010|3.3k

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

|The Lancet Oncology|2018|2.5k

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

|The Lancet|2014|2.2k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1.1k

Serum markers detect the presence of liver fibrosis: A cohort study

|Gastroenterology|2004|1.1k